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ABSTRACT The human anti-oncoprotein p53 is shown to
be a substrate of cdc2. The primary site of phosphorylation is
serine-315. Serine-315 is phosphorylated by both p60-cdc2 and
cyclin B-cdc2 enzymes. The phosphorylation of p53 is cell
cycle-dependent. The abundance of p53 also oscillates during
the cell cycle. The protein is largely absent from cells that have
just completed division but accumulates in cells during GI
phase. Phosphorylation by cdc2 might regulate the antiprolif-
erative activity of p53.
The polypeptide known as p53 was first described as a
cellular phosphoprotein that forms a complex with the large
tumor antigen (TAg) in simian virus 40 (SV40)-infected cells
(1). p53 also associates with the 58-kDa product of the E1B
gene in cells infected with adenovirus (2). Initially, p53 was
considered an oncoprotein since expression ofp53 assisted in
transformation of primary rodent cells (3). Subsequently, it
was found that most if not all established cell lines carry
mutant forms of p53, and mutant rather than wild-type genes
were used in early studies. The wild-type gene is not onco-
genic in typical assays and indeed can negate the effect of
certain oncogenes (4). This observation coupled with the
finding that mutations or full deletion of the p53 gene fre-
quently occur in natural tumors (5) has led to the realization
that p53 may normally act as an inhibitor of cell proliferation.
The biochemical role ofp53 in regulating cell proliferation has
yet to be defined.
Another element directly involved in eukaryotic cell pro-
liferation is the cdc2 protein kinase (6-11). cdc2 plays a broad
role in cell cycle control. In the fission yeast, cdc2 gene
function is required at two points during the cell cycle, before
DNA synthesis and at the initiation of mitosis (12). In
Xenopus oocytes cdc2 has been identified as a component of
the M phase-promoting factor (13, 14) and cdc2 function is
required for mitosis in mammalian tissue culture cells (15). It
is uncertain whether cdc2 function is required for entry into
S phase in vertebrate cells, but phosphorylation of SV40 TAg
by cdc2 directly promotes the initiation of viral DNA repli-
cation in vitro (16).
To understand how cdc2 functions in the cell cycle, it is
essential to identify substrates of the enzyme. cdc2 is pre-
dominantly a nuclear protein (15) and we have, therefore,
investigated the ability of cdc2 to phosphorylate known
nuclear phosphoproteins that might play a role in cell cycle
regulation. We show here that p53 is a cdc2 substrate.
MATERIALS AND METHODS
Cell Culture, Labeling, and Elutriation. Human CEM cells
were cultured in suspension at 37°C in RPMI 1640 medium
supplemented with 10o (vol/vol) fetal bovine serum. Cells
were maintained at 2-4 x 106 cells per ml.
For 32P labeling of proteins for tryptic peptide mapping, 1-2
x 108 exponentially growing CEM cells were incubated in 5
ml of phosphate-free Dulbecco's modified Eagle's medium
(DMEM) containing 5 mCi (1 Ci = 37 GBq) of inorganic
[32P]phosphate (ICN) for 1.5 hr at 370C.
Centrifugal elutriation and flow cytometric analysis of
CEM cells were as described for HeLa cells (9), except 2 x
109 CEM cells were loaded at a pump speed of 100 ml/min
and fractions were collected at pump speeds of 130, 150, 170,
190, 210, 230, 250, 270, 290, and 310 ml/min.
Purification of cdc2 Protein Kinase Complex and p53. Hu-
man cdc2 protein kinase complex was purified from HeLa
cells as described (17) except that after lysis by Dounce
homogenization the lysate was adjusted to 0.5 M NaCl and
further homogenized to salt-extract the nuclei prior to cen-
trifugation. This resulted in an approximately 5-fold increase
in cdc2 kinase activity recovered (J.R.B., unpublished data).
To obtain quantities of human p53 sufficient for in vitro
kinase experiments, a recombinant baculovirus (pEVSSH-
p53) was generated that contained human p53 coding se-
quences that had been cloned and characterized (18) (P.N.F.
and C.P., unpublished data). pEV55HpS3 was constructed
according to published procedures (19) using the transplace-
ment plasmid pEV5S and DNA from wild type baculovirus
Autographa californica (AcMPVL-1) (20). SF27 insect cells
(2.5 x 107 cells per 150-mm dish) were infected with
pEVSSHp53 (1-2 plaque-forming units per cell) and 48 hr
after infection cells were lysed and p53 protein was purified
using protein A-Sepharose beads to which the p53-specific
monoclonal antibody PAb421 (21) had been cross-linked (22).
Human p53 obtained by this approach displayed the correct
electrophoretic mobility and antibody specificity as de-
scribed (23). Similar quantities ofhuman p53 (=100 Ag per 107
SF27 cells) were routinely purified, as were obtained from
cells infected with pEV55p53 that expresses murine p53 (22).
Peptide Synthesis and Sequencing. Peptide CSH133 (RAA-
LPNNTSSSPQPKKKPLDGEY-using the single-letter
amino acid code) was synthesized on an Applied Biosystems
model 430A instrument using small-scale (0.1 mmol) rapid
cycles as t-Boc (t-butoxycarbonyl) symmetric anhydrides.
These cycles were modified to allow double coupling of
leucine, threonine, serine, lysine, and glutamic acid residues
first in dimethylformamide and then in dichloromethane.
Unreacted peptide was capped with acetic anhydride. Cou-
pling yields exceded 99% on each cycle. The peptide was
cleaved from the resin and deprotected in liquid HF contain-
ing anisole and dimethyl sulfide, 1:20 (vol/vol), for 2 hr at
-10°C. After ether extraction the peptide was purified by
high performance liquid chromatography and analyzed by
plasma desorption mass spectrometry.
Sequence analysis was done on a Applied Biosystems
model 473A protein sequencer using pulse-liquid delivery of
trifluoroacetic acid and vapor-phase delivery of trimethyl-
amine. After conversion, the product of each cycle was
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collected, mixed with 10 ml of Aquasol scintilation fluid, and
measured for radioactivity.
Immunoprecipitation and Kinase Reactions. Immunopre-
cipitations of CEM extracts were as described (24).
In vitro phosphorylation of purified p53 by purified cdc2
protein kinase was at 30'C for 30 min in 50 mM Tris-HCI, pH
8/10 mM MgCl2/1 mM dithiothreitol/0.1 mM ATP/10-30
ILCi of ['y-32P]ATP (New England Nuclear, 3000 Ci/mM). The
phosphorylation of purified p53 by anti-cyclin B and C160
immunoprecipitates utilized the same conditions described
above. The phosphorylation of the p53 synthetic peptide
(CSH133) used the same buffer conditions; the peptide con-
centration was 150 J.M. The phosphorylation of the peptide
was monitored by binding to P81 paper (Whatman) and
counting in liquid scintilation fluid. The in vitro phosphoryl-
ation of the endogenous CEM p53 was as follows. Lysates
were prepared as described (9), except the lysis buffer
contained 125 mM NaCl. The CEM lysate was adjusted to 50
mM Tris HCl, pH 7.5/10 mM MgCl2/1 mM dithiothreitol/0.1
mM ATP/10-20 ,Ci of [y-32P]ATP and incubated for 30 min
at 30°C. The reaction was then adjusted to 50mM EDTA and
immunoprecipitated with PAb421, a monoclonal antibody to
p53 (21).
In vitro phosphorylation of histone H1 by G6 and C160
immunoprecipitates was as described (24).
Peptide Mapping and Phospho Amino Acid Analysis. Im-
munopurified p53 that had been 32P-labeled in vitro or in vivo
or phosphorylated peptide CSH133 was digested with trypsin
as described by Beemon and Hunter (25). The resulting
peptides were resolved in two dimensions on 100-,m cellu-
lose thin-layer plates (EM Science) by electrophoresis at 800
V for 25-40 min at pH 1.9 in acetic acid/88% (vol/vol) formic
acid/water, 156:50:1794 (vol/vol), followed by ascending
chromatography in 1-butanol/pyridine/acetic acid/water,
75:50:15:60 (vol/vol). One-dimensional phospho amino acid
analysis was according to Draetta et al. (26).
RESULTS
cdc2 Phosphorylates p53 on Serine-315. To test whether
human p53 might be a cdc2 substrate, p53 was immunopu-
rifled from a baculovirus expression system. After incubation
with [y-32P]ATP, no endogenous kinase activity was detected
in the preparation of p53 (Fig. 1A). However, if p53 was
mixed with cdc2 kinase purified from HeLa cells, phosphor-
ylation of p53 was apparent in addition to the autophosphor-
ylation of the cyclin B subunit of cdc2 (Fig. 1A).
To investigate the phosphorylation of p53, we used a
T-lymphoblastoid cell line (CEM). Phosphorylation of en-
dogenous p53 in crude lysates could be observed by the
addition of [y_32P]ATP, followed by incubation at 30°C and
immunoprecipitation with PAb421, a monoclonal antibody
against p53 (21). An extract was prepared from CEM cells
and was preincubated with either control Sepharose, or
p13-Sepharose. p13 is a subunit of cdc2 (9, 27) and this
polypeptide coupled to Sepharose is an effective reagent for
clearing a cell lysate of cdc2 (10, 24). After addition of[y-32P]ATP to the cleared cell lysates, p53 was immunopre-
cipitated with PAb421. Preclearing the lysate with p13-
Sepharose resulted in a significant reduction of p53 phos-
phorylation (Fig. 1B). On average, lysates precleared with
p13-Sepharose had one-third the p53 kinase activity com-
pared to lysates precleared with control Sepharose, but on no
occasion was all activity removed. To be certain that the
apparent clearing of the p53 kinase activity by p13-Sepharose
was not due to binding of p53 to the beads, the amount of p53
protein in the precleared lysates was determined by immu-
noblot analysis. No significant difference in the amount of
p53 was observed between extracts precleared with control
Sepharose and p13-Sepharose (data not shown). Thus, p13-
A
cdc2
p52
B
- - + + + +
p53 - -M
1 2 3 4 5 6 2
FIG. 1. In vitro phosphorylation of p53. (A) Lanes: 1, reaction
mixture containing 160 ng of p53; 2, reaction mixture containing 320
ng of p53; 3, reaction mixture containing purified cdc2 protein kinase
and 160 ng of p53; 4, same as lane 3, except containing 320 ng of p53;
5 and 6, reaction mixtures containing purified cdc2 protein kinase
alone. Each reaction mixture was incubated with [y-32P]ATP and
subjected to SDS/PAGE. (B) In vitro phosphorylation ofp53 in crude
lysates prepared from human CEM cells. Lanes: 1, 500 ,g of CEM
lysate precleared with control Sepharose was incubated with [y-
32P]ATP and precipitated with anti-p53 (PAb421); 2, same as lane 1
except that the cell lysate was precleared with p13-Sepharose.
Sepharose, which has been shown to bind specifically to
cdc2, removes a significant fraction of protein kinase activity
that can phosphorylate p53 in a whole cell lysate. It should be
noted that the p53 in CEM cells is probably not wild type.
To examine whether cdc2 phosphorylates p53 at sites
utilized in vivo, two-dimensional tryptic peptide mapping of
p53 phosphorylated either in vivo or in vitro was performed.
In the CEM cell line, no less than 11 tryptic phosphopeptides
of p53 were resolved (Fig. 2A). A tryptic map of p53 phos-
phorylated in vitro by purified cdc2 protein kinase revealed
only four phosphorylated peptides, of which one, referred to
as peptide 3, was overwhelmingly the most heavily labeled
(Fig. 2B). A mixture of the tryptic digests of p53 phospho-
rylated in vivo and in vitro was also resolved in two dimen-
sions (Fig. 2C). It appears that the four sites phosphorylated
in vitro by the cdc2 protein kinase were also phosphorylated
in vivo. Most notably, the major fragment phosphorylated in
vitro (Fig. 2 B and C, peptide 3) was also a major site of
phosphorylation in vivo. Phospho amino acid analysis was
performed on peptide 3 that had been phosphorylated either
in vivo or in vitro. In both cases phosphoserine was detected
(Fig. 2D). These observations show that cdc2 can phosphor-
ylate p53 in vitro at sites that are phosphorylated in vivo. It
also becomes apparent that cdc2 is not the only kinase that
phosphorylates p53; this probably explains the inability of
p13-Sepharose to clear all of the kinase activity that phos-
phorylates p53.
At least four sites of phosphorylation have been identified
in murine p53 (28, 29). Among these is serine-312. Serine-312
is followed by a proline and, since cdc2 phosphorylation sites
invariably contain the motif Thr/Ser-Pro (16, 30), we tested
whether serine-315 [corresponding to murine serine 312 (18)]
might be a site of cdc2 phosphorylation. Accordingly, we
synthesized a peptide corresponding to amino acids 305-327
of human p53, which is expected to be cleavable at each end
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FIG. 2. Tryptic peptide mapping of p53. (A) Two-dimensional
tryptic peptide map of 32P-labeled p53 immunoprecipitated from
CEM cells. (B) Similar peptide map of p53 labeled in vitro by purified
cdc2 kinase. (C) Map of a mixture of p53 labeled in vitro and in vivo.
(A-C) First dimension was electrophoresis from right (-) to left (+)
and second dimension was ascending chromatography. Arrowheads
mark the electrophoretic origins. (D) One-dimensional phospho
amino acid analysis of peptide 3 labeled in vivo (lane 1) or in vitro
(lane 2). Migration of marker phosphoserine (P-ser), phosphothreo-
nine (P-thr), and phosphotyrosine (P-tyr) is indicated.
by trypsin, leaving a fragment containing serine-315. The
peptide was readily phosphorylated by cdc2 and after trypsin
digestion the phosphopeptide was resolved in two dimen-
sions (Fig. 3A). The migration of the synthetic peptide was
identical to that of tryptic peptide 3 from full-length human
p53 phosphorylated in vitro by cdc2 (Fig. 3 B and C).
Sequential degradation of the undigested phosphorylated
peptide and radioactivity in each amino acid released was
measured by scintillation counting. Although some 32p was
released during cycles 9 and 10 (serine-313 and -314, respec-
tively), the peak of 32p was released at cycle 11, which
corresponded to serine-315 (data not shown). Thus, serine-
315 is the major site of phosphorylation by cdc2 in human
p53.
FIG. 3. Phosphorylation of
peptide containing serine-315. (A)
Peptide CSH133 (RAALPNNT-
SSSPQPKKKPLDGEY) corre-
sponding to amino acids 305-327
of human p53 was phosphorylatedA in vitro by purified cdc2, digested
with trypsin, and resolved in two
dimensions. (B) p53 phosphoryl-
ated in vitro by cdc2 was digested
with trypsin and resolved in two
dimensions. (C) Map of a mixture
of materials in A and B. Arrow-
A heads mark the electrophoretic
origins.
Phosphorylation by p60-cdc2 and Cyclin B-cdc2. The en-
zyme preparation used in the previous series of experiments
(17) consisted primarily of cyclin B-cdc2. However, it also
contained low levels of an interphase form of the enzyme,
p60-cdc2 (D.B., unpublished observations). We thus asked
which of these two enzymes might be responsible for phos-
phorylation of p53. Lysates from exponentially growing
CEM cells were immunoprecipitated with either monoclonal
antibody C160, which recognizes the p60 subunit ofcdc2 (24),
or anti-cyclin B antibody (31). p53 was added as substrate and
was phosphorylated in each case (Fig. 4A). The C160 im-
munoprecipitates phosphorylated p53 to a greater extent at
all concentrations of p53 examined. The lower level of
phosphorylation in the anti-cyclin B precipitates does not
necessarily reflect reduced affinity for p53, since the ability
of these precipitates to phosphorylate histone H1 was also
reduced compared to the C160 precipitates (data not shown).
Tryptic peptides of p53 phosphorylated in vitro by the p60-
or cyclin B-associated cdc2 kinase were resolved in two
dimensions. Both enzymes predominantly phosphorylated
one major peptide (Fig. 4 B and C). When the two tryptic
digests were mixed the same spectrum of spots was observed
(Fig. 4D). The major site of phosphorylation with each
enzyme corresponds to that of peptide 3 in Fig. 2. Thus, both
cdc2 protein kinase complexes phosphorylate p53 at the same
sites, predominantly at serine-315.
Cell Cycle Regulation. The cell cycle oscillation of the
activity of cdc2-containing protein kinase complexes is well-
established in mammalian cells (9, 24, 26, 31). In particular,
the cyclin B-containing enzyme is most active during M
phase, whereas the p60-cdc2 enzyme is most active in
interphase.
To investigate the possible cell cycle regulation of p53
phosphorylation, CEM cells were fractionated by centrifugal
elutriation to obtain populations enriched at various stages of
,_ ~~~~~~~53
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FIG. 4. Phosphorylation of p53 in vitro by p60-cdc2 and cyclin
B-cdc2. (A) In vitro phosphorylation of 0, 0.1, 0.2, and 0.4 ,ug of p53
by anti-cyclin B immunoprecipitates of CEM cells (lanes 1-4) or by
C160 immunoprecipitates (lanes 5-8). CEM lysate (250 Mg) was
immunoprecipitated for each phosphorylation reaction. (B) Two-
dimensional tryptic peptide map of p53 phosphorylated by the C160
immunoprecipitate. (C) Two-dimensional tryptic peptide map of p53
phosphorylated by anti-cyclin B immunoprecipitate. (D) Two-
dimensional tryptic peptide map of a mixture of material in B and C.
Arrowheads mark the origins of electrophoresis.
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the cell cycle. Crude lysates of the elutriated fractions were
assayed for their ability to phosphorylate endogenous p53 or
were immunoprecipitated with C160 or with G6, an anti-cdc2
antibody, for histone H1 kinase assay. For reasons that are
not fully clear, antibody G6 can be used to preferentially
measure the activity of cyclin B-cdc2 (24).
The phosphorylation of p53 in the whole-cell lysate of each
elutriated fraction displayed clear cell cycle-dependence.
The greatest incorporation of phosphate into p53 occurred in
fraction S (Fig. 5B), in which a high percentage of cells were
in S phase (Fig. 5A). The histone kinase activity of p60-cdc2,
assayed with C160 immunoprecipitates, corresponded
closely with the phosphorylation of p53 in whole-cell lysates
(Fig. 5 B and C). The activity of cyclin B-cdc2 peaked one
or two fractions later in the elutriation profile as compared to
p60-cdc2 (Fig. SD).
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FIG. 5. Cell cycle regulation of p53 and cdc2 kinases. (A)
Flow-cytometric profiles of CEM cells fractionated by centrifugal
elutriation. Fractions 1, 5, and 8 (as indicated) are enriched in G1, S,
and G2/M populations, respectively. Open and solid triangles signify
2N and 4N DNA content (where N is the haploid amount of DNA).
(B-F) AS indicates asynchronous cells and the elutriation fractions
are indicated as lane labels. (B) In vitro phosphorylation of p53 in
whole cell lysates of elutriated cells. After incubation with [y-
32P]ATP, p53 was immunoprecipitated with PAb421. (C) Phosphor-
ylation of histone H1 by C160 immunoprecipitates of elutriated
fractions. (D) Phosphorylation of histone H1 by G6 immunopre-
cipitates of elutriated fractions. Equal amounts of protein (250 Ug)
were assayed in all cell lysates. (E) Total cell protein (300 ,Lg) from
elutriated fractions was analyzed by an immunoblot with PAb42W.
(F) Elutriated fractions were inoculated into fresh medium and
allowed to recover for 1 hr at 37°C. The cells were then pulse-labeled
with [32P]orthophosphate (1 mCi) in phosphate-free DMEM for 1 hr
at 37°C. Cell lysates were immunoprecipitated with PAb42W.
In a separate but similar experiment, we measured the level
of p53 protein in crude lysates in each elutriated fraction and
also the incorporation of [32P]orthophosphate into p53 in cells
briefly returned to culture after elutriation. The total amount
of p53 protein, detected by immunoblot analysis, varied
substantially in the various fractions. The protein was scarce
in those containing predominantly G1 populations and peaked
in fraction 4 (Fig. SE). In the later fractions the protein
became less abundant. There was likewise a differential rate
of incorporation of inorganic phosphate into p53 in each
elutriated fraction. About 2- to 3-fold more 32p was incorpo-
rated into p53 during the S and G2/M phases of the cell cycle
by comparison with G1-enriched fractions (Fig. 5F). This
subtle difference is probably due to the fact that cdc2 is only
one kinase that phosphorylates p53 and it may be that the
other kinase(s) involved is not cell-cycle regulated.
It is well-established that p53 accumulates after mitogenic
activation of quiescent cells (32); however, in continuous
culture the level of p53 has been reported to be constant
throughout the cell cycle in cells that are not virally trans-
formed (33). The cell cycle oscillation of p53 in CEM cells
implies that the timing of maximal incorporation ofphosphate
into p53, either in cell-free lysates or in vivo (Fig. 5), need not
precisely reflect the time of maximal activation of the kinases
of which p53 is a substrate. However, the results in Fig. S are
consistent with the likelihood that p53 is a substrate of both
p60-cdc2 and cyclin B-cdc2.
DISCUSSION
Although it increasingly appears that p53 normally acts as an
inhibitor of cell proliferation, its precise biochemical role is
not well-understood. However, it is of great interest that the
protein is phosphorylated by the cdc2 cell cycle-regulatory
kinase.
The ability of both p60-cdc2 and cyclin B-cdc2 to phos-
phorylate p53 suggests that the protein is likely to be phos-
phorylated at serine-315 for much of the cell cycle, except in
G1. There is little p53 in cells that have just completed
division and newly synthesized protein is expected to accu-
mulate in an underphosphorylated state during early G1,
during which no known form of cdc2 is catalytically active.
Since p60-cdc2 readily phosphorylates p53, serine-315 phos-
phorylation is expected to follow activation of this enzyme,
close to the onset of DNA replication. Further phosphoryl-
ation may occur duringM phase, during which cyclin B-cdc2
is active. Whether serine-315 retains phosphate during the G2
phase of the cell cycle is likely to depend on the time of
inactivation of p60-cdc2, which has not been accurately
determined, on the half-life of the p53 protein itself, which is
known to be short especially in nontransformed cells (34),
and also on phosphatase-dependent dephosphorylation of
serine-315. Determining the exact time of phosphorylation of
p53 by cdc2 in CEM cells is further complicated by the
presence of other kinases that phosphorylate p53.
It is perhaps surprising that p60-cdc2 and cyclin B-cdc2
phosphorylate p53 in such a similar manner. One very
probable role of cdc2-associated proteins is to regulate the
substrate specificity of the protein kinase (17) and some
differences in the specificity of these two enzymes may be
expected. However, histone H1, which is an M-phase sub-
strate of cdc2 (10), contains a subset of sites that are
phosphorylated during both interphase and M phase (35).
These might be sites susceptible to phosphorylation by both
p60-cdc2 and cyclin-cdc2.
p53 was originally identified as a protein that complexes
with TAg of SV40. It is intriguing, therefore, that TAg has
also been shown to be a cdc2 substrate (16). Both TAg and
p53 are nuclear proteins and in each case a region of the
molecule required for nuclear localization has been identi-
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fied. It is of interest that in TAg and p53 the site of cdc2
phosphorylation is in a very similar relative position to the
karyophylic site. Thus in TAg, threonine-124 is the site of
cdc2 phosphorylation (16) and the primary nuclear localiza-
tion signal lies between residues 126 and 133 (36). In p53, cdc2
phosphorylates serine-315 and the primary karyophilic site is
at residues 316-322 (37). For the TAg, deletion of residues
111-125 markedly alters the kinetics ofnuclear transport (38).
It is thus possible that phosphorylation by cdc2 might affect
the subcellular localization of TAg and p53.
In addition to p53, the product of the retinoblastoma gene
(Rb) is an antioncoprotein. There are interesting parallels
between the two polypeptides. Both are nuclear phosphopro-
teins that associate with proteins encoded by DNA tumor
viruses. SV40 TAg binds to both Rb and p53. For adenovirus,
ElA binds to Rb and E1B binds to p53 (2, 39). Furthermore,
both are phosphorylated in a cell cycle-dependent manner
(present study and ref. 40). It is likely that Rb is also a
substrate of cdc2 (41).
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